Liverpool biotech firm ChargePoint travels to New York to target export growth

Merseyside biotech firm ChargePoint Technology is heading to the US later this month to target new overseas markets.

The Liverpool-based company will showcase its precision containment valves to a number of pharmaceutical firms at the Interphex event in New York.

Chris Eccles, ChargePoint’s managing director, commented: “Interphex is one of the key events in the calendar for the biotech and pharma industry and it is very important to us.

“We will be meeting some of the biggest companies in the world and after establishing ourselves as leaders in innovation for the past seven years, we are confident that the technology we produce will be well-received, because we are talking about a game changer in this sector.”

ChargePoint, which operates from a facility in Speke, currently provides its containment valves to a number of US-based firms, pharma giants Johnson & Johnson, Merck, Ritedose, Roche Genentech and Pfizer.

While around one-fifth of its yearly revenue comes from the US, ChargePoint is hoping to grow that figure and expand its American client portfolio following the Interphex showcase.

Speaking further, Chris said: “While we have every confidence in our technology, it is not enough, however, just to manufacture an innovative product, it needs to be sold and customers need support. We go this far and further.”

In addition to its growing US footprint, ChargePoint Technology also counts China and India among its fastest growing export markets, as both territories adapt to meet the same regulatory requirements as the West.